Discipline of General Practice, University of Adelaide, SA 5005, Australia.
Maturitas. 2012 Jan;71(1):44-8. doi: 10.1016/j.maturitas.2011.10.004. Epub 2011 Nov 9.
Our pilot study tested the efficacy, acceptability and tolerability of DHA supplementation in addition to calcium and vitamin D in individuals with osteopenia.
40 participants were randomised to either algal oil containing 400mg docosahexanoic acid (DHA) daily or placebo. All participants received 1200 mg calcium carbonate with vitamin D(3) 1000 IU daily.
Bone mineral density (BMD) was measured at baseline and 12 months. Bone turnover was assessed with serum c-terminal telopeptides (CTx) at baseline and 12 months. Tolerability and acceptability were assessed using a validated questionnaire.
Mean CTx was suppressed after 12 months for all participants (p=0.04) with no difference in effect size between DHA and control groups (p=0.53). Changes in CTx at 12 months were significantly correlated with changes in BMD at the lumbar spine (p=0.01) and total proximal femur (TPF) (p=0.03). There was a non-significant trend towards rising BMD at 12 months. Participants rated the supplements as tolerable and acceptable, with few adverse events.
The combination of oral calcium, vitamin D(3) and DHA was safe, tolerable and acceptable when used for 12 months by osteopenic individuals in this pilot study. The combination had a positive effect on bone health as indicated by serum CTx, with no effect demonstrated from the addition of DHA 400mg. Changes in BMD at the lumbar spine and TPF were significantly correlated with changes in CTx, which may be useful in monitoring bone health and response to treatment.
我们的初步研究测试了在骨质疏松个体中补充 DHA（二十二碳六烯酸）联合钙和维生素 D 的疗效、可接受性和耐受性。
40 名参与者被随机分配到每日服用含有 400mg 二十二碳六烯酸（DHA）的藻油或安慰剂组。所有参与者每日接受 1200mg 碳酸钙和 1000IU 维生素 D(3)。
基线和 12 个月时测量骨矿物质密度（BMD）。基线和 12 个月时通过血清 C 端肽（CTX）评估骨转换。使用经过验证的问卷评估耐受性和可接受性。
所有参与者的平均 CTx 在 12 个月后均被抑制（p=0.04），DHA 和对照组之间的效果大小无差异（p=0.53）。12 个月时 CTx 的变化与腰椎（p=0.01）和总近端股骨（TPF）（p=0.03）BMD 的变化显著相关。12 个月时 BMD 呈上升趋势，但无统计学意义。参与者认为补充剂是可耐受和可接受的，仅有少数不良事件。
在这项初步研究中，骨质疏松个体口服钙、维生素 D(3)和 DHA 联合使用 12 个月是安全的、可耐受的和可接受的。联合使用对骨骼健康有积极影响，血清 CTx 显示，添加 400mg DHA 没有效果。腰椎和 TPF 的 BMD 变化与 CTx 的变化显著相关，这可能有助于监测骨骼健康和治疗反应。
